


Novel bispecific antibodies development for Metastatic Castration-Resistant Prostate Cancer



ONCOLOGY	Lead
Product Type	T cell engager, Bispecific antibody
Indication	mCRPC (Metastatic Castration-Resistant Prostate Cancer)
Target	PSMA (Prostate specific membrane antigen)
MoA(Mechanism of Action)	 <ol style="list-style-type: none"> 1. Binding to both PSMA expressing tumor cells and 4-1BB expressing T cells 2. Induction of T cell activation through intracellular signaling transduction 3. Tumor cell killing by cytokines secreted from activated T cell such as Interferon-gamma and granzyme-B.
Competitiveness	<ol style="list-style-type: none"> 1. Effective T cell activating bispecific antibody, T cell engager 2. Efficient bispecific antibody that activates T cell costimulatory receptor, 4-1BB 3. Unique format optimized for T cell activation
Development Stage	Lead
Route of Administration	Intravenous Injection